CA-VELODYNE-LIDAR
28.4.2020 14:02:06 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced a three-year agreement with EasyMile, a global leader in driverless technology and smart vehicle solutions. EasyMile uses Velodyne lidar sensors in production of its EZ10 autonomous passenger shuttles that are deployed on public and private roads in more than 30 countries around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200428005241/en/
EasyMile will enhance its EZ10 shuttle fleet with Velodyne’s state-of-the-art sensors for safe and efficient navigation on roadways. Electric and driverless, the EZ10 shuttle was the one of the first autonomous shuttles launched in April 2015. It has a track record of over 200 deployments and more than 600,000 km driven in autonomous mode and one of the most advanced technology currently available. The shuttle, which has capacity for up to 15 passengers, includes a built-in automated electric ramp to support accessibility for individuals with disabilities.
“For precise navigation in real time, the EZ10s use our algorithm that fuses data from a variety of perception sensors, including lidar and camera, and localization sensors, including GPS, INS and odometry. Velodyne lidars along with radar scan for objects, vehicles, animals and people that might pose a collision threat, feeding that information to the vehicle’s control software,” explained Olivier Pairot, EasyMile’s Director of Product Marketing. “By utilizing Velodyne sensors, we are able to best gather information on every part of our environment, both close to the vehicle and at longer ranges.”
“Velodyne’s high performance lidar technology is a key component in enabling our autonomous vehicles to deliver smart mobility in urban, suburban and private environments,” said Benoit Perrin, Managing Director and COO, EasyMile. “Velodyne’s solutions have the reliability, quality and production scale we are looking for to continue to grow our fleet worldwide.”
“The EasyMile EZ10 provides a shared, inclusive driverless shuttle solution that improves public transport by connecting hubs and in many cases, delivers a transport service where there otherwise wasn’t one available,” said Erich Smidt, Executive Director Europe, Velodyne Lidar. “These shuttles show how Velodyne lidar sensors provide real-time perception data that enables safe and reliable operation for autonomous vehicles across business parks, public transport connections, university campuses and more.”
Velodyne’s sensors are optimized for outstanding indoor and outdoor performance, operating in a variety of light conditions. By combining high-resolution 3D perception with a broad vertical field of view, they can accurately detect a variety of objects.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About EasyMile
EasyMile is a global leader in driverless technology and smart vehicle solutions. The fast-growing company develops software to automate transportation platforms without the need for dedicated infrastructure. EasyMile’s cutting-edge technology is revolutionizing passenger and goods transportation, offering new mobility options. EasyMile has already deployed close to 250 driverless projects in more than 30 countries and transported people over 600,000 km. Clients include the world’s largest transport operators, city authorities, airports, corporations, business parks, and universities. Founded in 2014, EasyMile has a global presence with headquarters in Toulouse (France) and regional offices in Denver (USA), Berlin (Germany), Adelaide (Australia) and Singapore. The Company employs over 200 highly skilled and passionate employees specializing in robotics, computer vision and vehicle dynamics. Besides the two founders, CEO Gilbert Gagnaire and Board Member Philippe Ligier, EasyMile benefits from the backing of minority shareholders and strategic partners, Alstom, Continental and Bpifrance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom